Cardio Diagnostics Holdings Inc
CDIO
查看详细走势图
3.520USD
+0.160+4.76%
收盘 12/24, 13:00（美东）报价延迟15分钟
6.22M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.76%
5天
+24.82%
1月
+10.69%
6月
+0.57%
今年开始到现在
-87.20%
1年
-88.38%
查看详细走势图
TradingKey Cardio Diagnostics Holdings Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Cardio Diagnostics Holdings Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名238/404位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价60.00。中期看，股价处于下降通道。近一个月，市场表现很强，基本面评分较高，但很强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cardio Diagnostics Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
60.000
目标均价
+1227.43%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cardio Diagnostics Holdings Inc亮点
亮点风险
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
业绩高增长
公司营业收入稳步增长，连续3年增长3572.63%
业绩增长期
公司处于发展阶段，最新年度总收入34.89K美元
利润高增长
公司净利润处于行业前列，最新年度总收入34.89K美元
估值高估
公司最新PE估值-1.07，处于3年历史高位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值24.12K
Cardio Diagnostics Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cardio Diagnostics Holdings Inc简介
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
公司代码CDIO
公司Cardio Diagnostics Holdings Inc
CEODogan (Meeshanthini V)
网址
常见问题
Cardio Diagnostics Holdings Inc(CDIO)的当前股价是多少？
Cardio Diagnostics Holdings Inc(CDIO)的当前股价是 3.520。
Cardio Diagnostics Holdings Inc的股票代码是什么？
Cardio Diagnostics Holdings Inc的股票代码是CDIO。
Cardio Diagnostics Holdings Inc股票的52周最高点是多少？
Cardio Diagnostics Holdings Inc股票的52周最高点是31.500。
Cardio Diagnostics Holdings Inc股票的52周最低点是多少？
Cardio Diagnostics Holdings Inc股票的52周最低点是2.424。
Cardio Diagnostics Holdings Inc的市值是多少？
Cardio Diagnostics Holdings Inc的市值是6.22M。
Cardio Diagnostics Holdings Inc的净利润是多少？
Cardio Diagnostics Holdings Inc的净利润为-8.38M。
现在Cardio Diagnostics Holdings Inc(CDIO)的股票是买入、持有还是卖出？
根据分析师评级，Cardio Diagnostics Holdings Inc(CDIO)的总体评级为--，目标价格为60.000。
Cardio Diagnostics Holdings Inc(CDIO)股票的每股收益（EPS TTM）是多少
Cardio Diagnostics Holdings Inc(CDIO)股票的每股收益（EPS TTM）是-3.199。
相关品种
